BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
Status:
Withdrawn
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effect of blisibimod plus standard of care versus
placebo plus standard of care alone on the proportion of subjects achieving improvement in
renal disease parameters.